Corporate Overview
Theratechnologies (TSX: TH) is a specialty pharmaceutical company listed on the Toronto Stock Exchange for over 15 years. To maximize its long term value, Theratechnologies develops innovative therapeutic products in order to bring them to market. The Company’s strategy is to focus on indications that meet the following criteria:
- Have a competitive edge over products currently marketed or in development
- Have a straightforward regulatory path and a manageable clinical program
- Be aimed at a speciality market where commercial rights can be retained
- Have the potential for attractive profit margins and a rapid payback on investment
Portfolio of Products
Our lead product, EGRIFTA® (tesamorelin for injection), is the first and only treatment approved by the U.S. Food and Drug Administration indicated to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. EGRIFTA® will be exclusively commercialized in the United States by EMD Serono pursuant to a collaboration and licensing agreement. EGRIFTA® is the proposed brand name to be used globally.*
Our strategy is now focused on the regulatory approval and commercialization of tesamorelin in additional HIV-associated lipodystrophy markets (including Europe, Canada and Latin America), as well as on the development of programs evaluating growth-hormone releasing factors in other medical conditions.
Moreover, two independent exploratory studies sponsored by the National Institutes of Health in the United States are evaluating tesamorelin, as an investigational new drug, for the treatment of growth hormone deficiency associated with abdominal obesity as well as for the treatment of pre-Alzheimer's syndrome.
Finance
Theratechnologies has adopted a sound financial strategy governing cash position and cash flow management. Maintaining a solid balance sheet is a corporate priority that underpins Theratechnologies’ growth strategy and, ultimately, assures its success in developing promising therapies.
*Please note that EGRIFTA® has not received approval for use from Health Canada and that U.S. patients and/or U.S. healthcare professionals seeking information on EGRIFTA® should refer to EMD Serono for more information.